Gou-Teng-San (GTS) for adults with episodic migraine

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a double-blind, randomized, placebo-controlled Phase 3 trial comparing oral Gou-Teng-San (GTS) to matched placebo in adults aged 18–70 with episodic migraine. Participants are randomized to receive GTS or placebo and will be followed to measure changes in migraine frequency, migraine-related symptoms, and the impact of migraine on daily life. Eligibility requires a 28-day screening diary showing 6–14 headache days with at least 4 qualifying migraine days, and limited or stable use of preventive migraine medications. Safety and tolerability are monitored throughout the trial.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adults aged 18 to 70 years.
* History of episodic migraine for at least 12 months before screening, meeting the International Classification of Headache Disorders, 3rd edition (ICHD-3) criteria, or clinically diagnosed migraine with no more appropriate ICHD-3 diagnosis.
* During the 28-day screening period, participants must meet criteria for episodic migraine, defined as headache occurring on \>=6 and \<=14 days, of which \>=4 days meet at least 1 of the following: (1) ICHD-3 criteria C and D for 1.1 migraine without aura; (2) ICHD-3 criteria B and C for 1.2 migraine with aura; (3) probable migraine (missing 1 migraine criterion); or (4) headache considered to be migraine based on a positive response to migraine-specific acute treatment (e.g., a triptan or an ergotamine derivative).
* Not receiving preventive migraine medication for at least 5 half-lives before enrollment, or receiving no more than 1 preventive migraine medication at a stable dose and regimen for at least 2 months before informed consent, whether for migraine or another medical condition (e.g., propranolol for hypertension).
* Body mass index (BMI) between 17.5 and 37.5 kg/m2, and body weight between 35 and 120 kg.
* Adequate compliance with headache diary completion during screening, defined as completion on at least 24 of 28 days (\>=85%), with diary data considered acceptable by the investigator.
* Able to comply with study restrictions and complete all protocol-required study procedures.
* Able to understand and sign the informed consent form.
* No major cardiovascular, hepatic, or renal disease.

Exclusion Criteria:

* Known allergy or hypersensitivity to Gou-Teng-San or any of its ingredients.
* Receipt of botulinum toxin type A injections in the head, face, or neck for any reason within 4 months before screening.
* Use of opioid-containing or barbiturate-containing medications on more than 4 days per month.
* Lack of efficacy after at least 3 months of treatment at accepted migraine treatment doses in 2 or more of the following preventive medication classes: (1) topiramate or valproic acid; (2) flunarizine; (3) amitriptyline, venlafaxine, or duloxetine; (4) atenolol or propranolol.
* Use of migraine treatment interventions within 2 months before screening, such as nerve block or transcranial magnetic stimulation.
* Clinically significant hematologic, cardiac, renal, endocrine, pulmonary, gastrointestinal, urinary, neurologic, hepatic, ophthalmologic, psychiatric, or other disease that, in the investigator's judgment, would interfere with study participation or study procedures.
* Participation in another clinical trial of a drug or medical device within 2 months before screening, or within 5 half-lives of the investigational product used in that trial, whichever is longer.
* Use of other Chinese herbal medicines within 4 weeks before screening.
* Previous exposure to monoclonal antibodies targeting the calcitonin gene-related peptide (CGRP) pathway or CGRP receptor antagonists.
* History of alcohol or drug abuse within the past 2 years.
* Women who are breastfeeding, have a positive pregnancy test at screening, or are unwilling to use contraception during the study if of childbearing potential.
* Any other condition or circumstance that, in the investigator's judgment, would make the participant unsuitable for the study or unlikely to complete the study successfully.

Where it's running

• Chung Shan Medical University Hospital
  Taichung, South, Taiwan Recruiting

Study contacts

• Study coordinator: Chueh-Yi Tsai, MD, MS
• Email: neurojoule@gmail.com
• Phone: 886-4-2473-9595

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Real-world use of anti-CGRP medicines for preventing migraine

  This project will follow people with episodic or chronic migraine who start anti-CGRP medicines to see if the treatments reduce migraine frequency and side effects over two years.

  Recruiting at 25 sites Hospital Universitari Vall d'Hebron Research Institute · Miami, Florida and 25 other locations · NCT07159750

• i-NEED: New migraine drugs database

  This project will collect real-life data to see how new migraine treatments—anti‑CGRP antibodies, gepants, ditans, and a sumatriptan‑naproxen combo—work and how well adults with episodic or chronic migraine tolerate them.

  Recruiting at 2 sites IRCCS San Raffaele Roma · Milan, Italy and 1 other locations · NCT07103694

• Effects of Atogepant on Neurophysiology and Biomolecules in Migraine

  This study is testing if a new migraine medication called atogepant can change brain activity and biochemistry in people who have frequent migraines.

  Recruiting IRCCS National Neurological Institute "C. Mondino" Foundation · Pavia, PAVIA · NCT06882122

• Analyzing CGRP Levels in Migraine Patients by Age and Sex

  This study looks at the levels of a substance linked to migraines in people with migraines and healthy individuals to see how age and sex might affect treatment responses.

  Recruiting Hospital Universitari Vall d'Hebron Research Institute · Barcelona, Barcelona · NCT06674772

• Assessing the safety and effectiveness of Atogepant for migraine prevention in Korean adults

  This study is testing how well and safely Atogepant works for preventing migraines in Korean adults who have chronic or episodic migraines.

  Recruiting at 36 sites AbbVie · Busan, Busan Gwang Yeogsi and 35 other locations · NCT06603558

• Using Atorvastatin to prevent episodic migraines

  This study is testing whether taking Atorvastatin can help people who get frequent migraines have fewer attacks each month.

  Recruiting at 3 sites Phase 2 St. Olavs Hospital · Bergen and 5 other locations · NCT06248671

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.